Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Anticancer Res 30(10):4317-23 (2010) PMID 21036758
There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.
Version: za2963e q8za5 q8zb8 q8zc4 q8zdd q8zed q8zfb q8zg2